What Causes SDTM, ADaM and SEND Validation Failures
SDTM, ADaM, and SEND datasets form the backbone of regulatory submissions to the FDA, PMDA, and other agencies. Yet validation failures in these datasets remain one of the most common obstacles to achieving submission readiness. Understanding why these failures occur...
How to Choose SEND Dataset Services in 2026
Why Selecting the Right SEND Dataset Service Matters FDA-compliant SEND dataset services determine whether your nonclinical submission clears the gateway or gets rejected. With SENDIG v3.1.1 now required for studies starting after March 15, 2023, and SENDIG-Genetox v1.0 mandated for...
Connecting Preclinical and Clinical Data in Biopharma
Clinical data automation platforms have become essential for large biopharma R&D teams working to bridge the gap between preclinical findings and clinical outcomes. When your organization invests significant resources in discovery and nonclinical studies, that data needs to flow into...
Produce a Study Report + SEND Dataset in 2–3 Weeks
Most nonclinical CROs take 8 to 10 weeks to deliver a study report and its SEND dataset, because two teams rebuild the same data twice. Here's how producing both from one governed source cuts that to 2 to 3 weeks...
SEND Datasets: The Complete Guide
SEND datasets are the standardized, machine-readable files the U.S. FDA requires for nonclinical study data in most drug and biologics submissions. If you run toxicology studies, assemble regulatory filings, or manage data at a CRO, SEND datasets are no longer...
5 SEND Compliance Challenges Nonclinical CROs Must Solve
This article breaks down the real SEND compliance challenges that nonclinical CROs face, grounded in current FDA and CDISC requirements, and shows where disciplined process and the right tooling change the outcome. We write this for toxicologists, regulatory affairs professionals,...
The Business Case for Automating Nonclinical Study Reports
The study report and its SEND dataset are built twice from the same data. Automating nonclinical study reports deletes that duplication, cuts cost 30 to 50 percent, and removes the inconsistencies that trigger FDA queries.
FDA SEND Requirements for Nonclinical Studies: Which Studies Need SEND Datasets in 2026?
Complete FDA SEND guide: which nonclinical studies require SEND datasets, SENDIG 3.1.1, DART, AR, Genetox deadlines, GLP rules, and IND/NDA scope explained.
AI in Nonclinical Reporting: From Hype to Real Workflow
Discover how AI is transforming nonclinical study reporting, from automated Module 2.4 drafts to FDA-compliant eCTD outputs. What is working, what is not, and what the FDA's 2025 guidance requires.
SEND Dataset Quality: Why Passing the Validator Is Only Half the Battle
Learn why SEND datasets fail FDA review even after passing validators, what the 2026 TCG requires, and how PointCross guarantees submission-ready quality.
